老年非霍奇金淋巴瘤的治疗相关特点及预后
摘要
目的探讨老年非霍奇金淋巴瘤的治疗相关特征和预后。方法回顾性分析65岁以上非霍奇金淋巴瘤患者的治疗相关性特征、毒性及预后的关系。结果所有老年非霍奇金淋巴瘤患者接受化疗,中位化疗周期数为6个周期。老年患者有无合并疾病和药物减量无明显相关性,但和患者体能状态评分密切相关(P<0.05)。骨髓抑制严重程度和患者化疗药物是否调整剂量、患者有无并发症,无明显相关性和ECOG评分状态有关(P<0.05)。ECOG评分、治疗模式与总生存时间密切相关,差异有统计学意义(P<0.05);是否有合并发病,化疗是否调整剂量和生存时间无明显相关性。结论老年非霍奇金淋巴瘤患者并发症多见,近半数患者化疗需要通过剂量调整或减少药物完成。合并疾病及化疗药物调整剂量均对生存无明显影响,患者ECOG评分状态、治疗模式影响总生存时间。
引文
1 Roman E,Smith AG.Epidemiology of lymphomas[J].Histopathology,2011;58(1):4-14.
2 陈冰,张帆,卢林明,等.中国皖南地区728例恶性淋巴瘤的构成分析[J].中国临床药理学与治疗学,2013;18(8):388-93.
3 Jaffe ES.The 2008 WHO classification of lymphomas:implications for clinical practice and translational research[J].Hematol Am Soc Hematol Educ Program,2009;523-31.
4 Cheson BD.New staging and response criteria for Non-Hodgkin lymphoma and Hodgkin lymphoma[J].Radiol Clin North Am,2008;46(2):213-23.
5 Chen AP,Setser A,Anadkat MJ,et al.Grading,dermatologic adverse events of cancer treatments:the Common Terminology Criteria for Adverse Events Version 4.0[J].J Am Acad Dermatol,2012;67(5):1025-39.
6 Fu JB,Lee J,Smith DW,et al.Frequency and reasons for return to the primary acute care service among lymphoma patients undergoing inpatient rehabilitation[J].PM&R:J Injury Func Rehabilit,2014;6(7):629-34.
7 Link BK,Brooks J,Wright K,et al.Diffuse large B-cell lymphoma in the elderly:diffusion of treatment with rituximab and survival advances with and without anthracyclines[J].Leuk Lymphoma,2011;52(6):994-1002.
8 邸鑫,王颖,李小丰,等.老年淋巴瘤 72 例临床分析[J].中国老年学杂志,2013;33(8):3756-7.
9 Luciani A,Ascione G,Marussi D,et al.Clinical analysis of multiple primary malignancies in the elderly[J].Med Oncol,2009;26(1):27-31.
10 Wang HT,Yang B,Cai LL,et al.Analysis for clinicopathological features,therapy and prognosis of 30 elderly patients with non-Hodgkin′s lymphoma[J].Exp Hematol,2013;21(6):1464-70.
11 Park S,Han B,Cho JW,et al.Effect of nutritional status on survival outcome of diffuse large B-cell lymphoma patients treated with rituximab-CHOP[J].Nutr Cancer,2014;66(2):225-33.
12 陈曦,王欢,张勇,等.老年非霍奇金淋巴瘤个体化分组治疗的疗效[J].中国老年学杂志,2015;35(6):3018-9.
2 陈冰,张帆,卢林明,等.中国皖南地区728例恶性淋巴瘤的构成分析[J].中国临床药理学与治疗学,2013;18(8):388-93.
3 Jaffe ES.The 2008 WHO classification of lymphomas:implications for clinical practice and translational research[J].Hematol Am Soc Hematol Educ Program,2009;523-31.
4 Cheson BD.New staging and response criteria for Non-Hodgkin lymphoma and Hodgkin lymphoma[J].Radiol Clin North Am,2008;46(2):213-23.
5 Chen AP,Setser A,Anadkat MJ,et al.Grading,dermatologic adverse events of cancer treatments:the Common Terminology Criteria for Adverse Events Version 4.0[J].J Am Acad Dermatol,2012;67(5):1025-39.
6 Fu JB,Lee J,Smith DW,et al.Frequency and reasons for return to the primary acute care service among lymphoma patients undergoing inpatient rehabilitation[J].PM&R:J Injury Func Rehabilit,2014;6(7):629-34.
7 Link BK,Brooks J,Wright K,et al.Diffuse large B-cell lymphoma in the elderly:diffusion of treatment with rituximab and survival advances with and without anthracyclines[J].Leuk Lymphoma,2011;52(6):994-1002.
8 邸鑫,王颖,李小丰,等.老年淋巴瘤 72 例临床分析[J].中国老年学杂志,2013;33(8):3756-7.
9 Luciani A,Ascione G,Marussi D,et al.Clinical analysis of multiple primary malignancies in the elderly[J].Med Oncol,2009;26(1):27-31.
10 Wang HT,Yang B,Cai LL,et al.Analysis for clinicopathological features,therapy and prognosis of 30 elderly patients with non-Hodgkin′s lymphoma[J].Exp Hematol,2013;21(6):1464-70.
11 Park S,Han B,Cho JW,et al.Effect of nutritional status on survival outcome of diffuse large B-cell lymphoma patients treated with rituximab-CHOP[J].Nutr Cancer,2014;66(2):225-33.
12 陈曦,王欢,张勇,等.老年非霍奇金淋巴瘤个体化分组治疗的疗效[J].中国老年学杂志,2015;35(6):3018-9.